Overview of management options for ocular adnexal lymphoma

Enas Abdulkarim Alkhoutani, Razan Mohammed Jan

Abstract:

This review will encompass the incidence, histology, immunophenotyping, clinical featues, diagnosis methods. Finally, traditional (surgery, radiotherapy, chemotherapy) and newer forms of therapy (immunotherapy and radioimmunotherapy) will be reviewed. Electronic comprehensive search was performed through medical databases; PubMed/ MIDLINE, Embase, and science-direct, for relevant articles discussing the ocular adnexal lymphoma management approaches, as well as studies showing the, search was to identified studies that were published through past period to December,2017The incidence of OAL, specifically ocular adnexal MALT lymphoma, has risen worldwide over the last couple of decades. Advances in our understanding of the immunophenotypic and genetic changes in lymphoma cell lines have caused a better understanding of the pathogenesis of the illness. The function of C. psittaci in the pathogenesis in the pathogenesis of ocular adnexal MALT lymphoma and the use of anti-biotics as a therapy alternative still need to be clarified by further collaborative international studies. Staging and histologic subtyping are essential in the design of optimum therapeutic program and determination of prognosis, as about 15% of situations of OAL existing with disseminated illness. A new TNM-based staging system has been created that will permit more accurate assessment of the risk of systemic disease and lymphoma-related death. New modalities of treatment including immunotherapy with anti-CD20 antibody and radioimmunotherapy offer distribution of improved cure rate and the delivery of curative treatment at much lower doses of radiation.

Introduction:

Lymphomas of the ocular adnexa are a heterogeneous group of lymphomas that represent approximately 1% to 2% of all non-Hodgkin lymphomas [1] and about 7% to 8% of extranodal lymphomas [2].Ocular adnexa consists of orbit, extraocular muscles, conjunctiva, eyelids, lacrimal gland, and apparatus. The incidence of ocular adnexal lymphoma (OAL) has enhanced by 6.3% every year in the duration from 1975 to 200 [1], [3] more quickly compared to nonHodgkin lymphomas at other extranodal sites. The medical diagnosis and treatment of OAL, with certain reference to eye adnexal marginal area lymphoma of mucosa linked lymphoid tissue kind (MALT) type (OAML) have been recently evaluated by several scientists [4].

OAL consist of both primary extranodal lymphomas, which comprise the majority of cases, and secondary tumors in patients with systemic lymphoma [5], [6].The percentage of second OAL in most collection arrays from 10% to 32% [5], [6].Ninety-five percent to 100% of reported situations of OAL are B-cell neoplasms and the bulk are reduced grade. Extranodal marginal area lymphoma of mucosaassociated lymphoid tissue (MALT) type is the most common histologic subtype of primary OAL, constituting concerning 35% to 80% of situations [5], [6].Follicular lymphoma and diffuse large B-cell lymphoma account for around 20% and 8% of primary OAL in the majority of Western series, with really little percents of mantle cell lymphoma, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma [5], [6].The proportion of MALT lymphoma amongst primary OAL is reported to be higher (80% to 90%) in collection from Japan and Korea and takes place in younger patients [7].Rare instances of primary T-cell lymphoma of the orbit have been reported, [8] whereas ocular adnexal involvement by Hodgkin lymphoma is extremely uncommon and constantly as a second manifestation instead of primary [8].

This review will encompass the incidence, histology, immunophenotyping, clinical featues, diagnosis methods. Finally, traditional (surgery, radiotherapy, chemotherapy) and newer forms of therapy (immunotherapy and radioimmunotherapy) will be reviewed.

Methodology:

Electronic comprehensive search was performed through medical databases; PubMed/ MIDLINE, Embase, and science-direct, for relevant articles discussing the ocular adnexal lymphoma management approaches, as well as studies showing the, search was to identified studies that were published through past period to December,2017, in English and containing only human subjects. Furthermore, references lists of included studies were scanned for more relevant articles.

Discussion:

Histology and Immunophenotype

Early series of lymphoproliferative illness of the ocular adnexa, before the extensive application of immunophenotyping and molecular researches, and some more recent series in the ophthalmologic literature, have included classifications of reactive lymphoid hyperplasia and atypical lymphoid hyperplasia [9].Lymphoproliferative conditions consisting of lymphoid hyperplasias are the commonest pathology in the orbit, with lymphomas making up 55% of all orbital malignancies [10].Difficulties in diagnosis of lymphoma and hence, the existence of the term atypical lymphoid hyperplasia connects to the tiny dimension of the specimen, lack of fresh tissue for circulation cytometry, and the difficulty of identification of B-cell clonality by IgH gene rearrangement studies. As extranodal marginal area lymphoma of mucosaassociated lymphoid tissue or MALT lymphoma, [11] makes up the largest single group of OAL, this will certainly be taken into

consideration separately. The other histologic types of primary OAL show features much like those occurring in other extranodal sites.

Table 1. Immunophenotype analysis of ocular adnexal lymphoproliferative lesions

Type	CD 3	CD 5	CD10	CD20	CD23	CD43	CD79	Bcl-2	Bcl-6	Cyclin D1
EMZL	-	-	-	+	-	+	+	-	-	-
Follicular	-	-	+	+	±	-	-	+	+	-
Mantle cell	-	+	-	+				-		+
Lymphoplasmacytic	-	+	-	+	+					
Diffuse large B-cell lymphoma	-	-(+)	+ (25% – 50%)	+			+			

- **Diagnosis of ocular adnexal lymphoma**

Clinical and imaging information cannot be used to make the diagnosis of OAL with certainty. Medical diagnosis is made based upon a combination of histopathologic, immunophenotypic, and molecular hereditary info. Diagnostically, three concerns are asked: (1) Is the lesion malignant (OAL), transitional (atypical RLH), or benign (RLH)? (2) What particular sort of OAL exists? (3) Can details prognostic attributes be identified? Routine histologic evaluation can typically address the concern of the level of malignancy. However, because the WHO classification hinges on immunophenotype and molecular genetic data, lym phoproliferative lesions should undergo IPA for B-cell and T-cell markers, heavy and light chain limitation, CD5, CD10, CD23, cyclin D1, and bcl-2. When possible based on the quantity of available tissue, circulation cytometry ought to be carried out due to its measurable nature. Immunophenotypic evaluation can respond to a number of basic inquiries, such as cell kind circulation and clonality vis-a-vis restriction of light chain to k or l expression. The histologically similar mantle cell and marginal cell tumors could usually be distinguished owing to the differential expression of CD5.

Molecular hereditary analysis for gene reformations of the IgG heavy chain could determine clonality at a far more delicate degree but could provide falsepositive data (especially in PCR-amplified research studies) based upon tasting problems. One problem regarding prognosis involves the definition of clonality. It has been questioned whether lesions showing proof of clonal proliferation yet that are or else believed to stand for responsive and not neoplastic processes are, in fact, very early or precursor lymphomas, and whether techniques, specifically those that rely upon extreme amplification of little examples of DNA, could artifactitiously develop the illusion of clonality. When the category of OAL was based upon nuclear functions, focus was put on repairing a few of the sampling in B5 fixative and preserving some in an unfixed state. Although fresh tissue is still thought about remarkable for IPA and molecular genetic analysis, renovations in antigen access techniques enable tissue addiction in 4% neutral buffered formalin. Flow cytometric studies still need unfixed tissue. Prebiopsy consultation with the pathologist is still suggested for optimum sampling evaluation.

- **Clinical evaluation and staging of the patient with ocular adnexal lymphoma**

Management of OAL is efficiently an integrated multidisciplinary undertaking requiring an extensive hosting evaluation. The significance of extensive hosting was demonstrated by a study showing a consistent dynamic rise in the illness stage as the extent of assessment increased [12].A comprehensive checkup by a medical professional knowledgeable about lymphoma is ideal. The use of ancillary staging researches has evolved with the growth of new imaging methods. Imaging and fine-needle biopsy have replaced laparotomy, although some inquiry the capacity of fine-needle aspiration biopsy to acquire diagnostically representative specimens. A current case-based survey of radiation specialists with expertise in managing lymphoma suggested the list below research studies: complete blood count, hepatic enzyme degrees, lactate dehydrogenase, CT of the

abdominal area and pelvis, chest radiography, CT of the upper body, and reciprocal bone marrow aspirates more than half the moment [13].In one research study, a quarter of patients with stage IV disease were updated from phase I based on bone marrow biopsy, highlighting its relevance. If conjunctival or eyelid OAL is identified clinically, MRI or CT of the orbit is shown for hosting. In one study, 50% of patients with obviously singular conjunctival illness had actually orbital condition disclosed by neuroimaging [14].If there is palpable cervical adenopathy, imaging of this region is executed too. The role of positron-emission tomography (PET) scanning in lymphoma hosting and even more especially in hosting of OAL is not established. PET has higher level of sensitivity in detecting abnormalities than does CT or MRI, however the relevance of minimal sores is not known.

- **Management of ocular adnexal lymphoma**

The selection of treatment for OAL depends on the specific tumor type and its staging. Conflict exists about whether OAL is curable. Those who think so pursue much more hostile but potentially poisonous therapies, whereas those who believe it is not curable could deal with indolent illness only as it becomes symptomatic or changes to high-grade lymphoma. Various other medical professionals will treat the patient based upon an attempt to stop makeover to a top-quality lymphoma. Sometimes, observation without treatment is selected.

Surgery

Although surgery can be used for certain cases of lymphoma and has been specifically advised for stage I MALT systemic lymphoma in some sites, this modality is commonly reserved for chosen cases of OAL. This strategy is due partially to the close association of important frameworks incorporated with the often diffuse or multicentric nature of OAL. Excision might be most ideal for localized lesions of the conjunctiva and orbit [15], [16].

Radiation

Radiation has been one of the most often utilized modality for treating OAL, because lots of patients existing with localized disease. Interpretation of researches of radiation therapy of OAL has been confused by the small patient number, making use of early classifications, or the grouping of situations by tumor" grade." Electron or photon irradiation can be used depending upon the site and extent of condition. A wide variation of doses has been recommended, ranging from lows of 15- 20 Gy approximately 40 Gy. Typical doses are 28 to 36 Gy for low-grade OAL and 30 to 40 Gy for high-grade condition. Dispute exists concerning the use of lens securing to reduce cataractogenesis. Some researches show no result on regional recurrence, whereas in others, all reappearances have occurred in patients whose lenses were protected [17], [19], [20].Difficulties have been noted at a higher rate (up to 50%) in research studies with proof of close sensory follow-up.

One research study has used the WHO category and examined the dose-response of radiation. The local 5-year control rate of EMZL-MALT was 81% with dosages less than 36 Gy however 100% with dosages greater than 30 Gy. There appears to be differential vulnerability of numerous kinds of OAL, with follicular lymphoma replying to greater and reduced dosages at a 100% rate. However, it is unclear that successful neighborhood control as reported by numerous studies affects the ultimate result of illness. Regional control despite having stage IV-EA condition was good even though survival was much less. The information of Jenkins et alia mentioned previously as well as that of others recommend that longer follow-up is needed to evaluate general therapy impact [17].Recurrences of low-grade types are typically treatable with local techniques. The use of local brachytherapy with strontium has been reported but appears to be connected with considerable varieties of regional reappearances as well as ocular poisoning [21].

Chemotherapy

A comprehensive conversation of chemotherapy for lymphoma is beyond the scope of this article. With singular OAL, systemic chemotherapy is not thought to be suggested, other than with DLBCL. Chemotherapy for OAL when it belongs to stage II or greater condition has included making use of standard routines for systemic lymphoma, including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), chlorambucil, along with many other combinations of agents.

Cryotherapy

Cryotherapy has been used infrequently for OAL, with varying success. Normally, it is utilized in patients with conjunctival lymphoma to minimize tumor bulk [16].

Interferon treatment

Interferon (IFN) has been used in the treatment of systemic lymphoma for over 20 years. There are scattered reports of the regional use of IFN-a for OAL [22].Five patients with singular conjunctival condition (4 with stage IE and one with stage IIA condition in remission after chemotherapy) were treated with intralesional IFN-a, 1,500,000 IU three times regular for 4 weeks complied with by 1,000,000 IU 3 times regular for 4 weeks and after that 1,000,000 IU every 2 weeks 4 times. A first total response was reported for all patients, and 80% were disease free with brief follow-up. The patient with stage IIA condition passed away of systemic lymphoma 1 year later on. Side effects consisted of a flulike syndrome. Long-term studies with even more patients assessing local and systemic recurrences are needed before interferon could end up being an established therapy for OAL.

Antilymphocyte antibody treatment

Antilymphocyte antibodies stand for the newest kind of lymphoma treatment Using antibodies to CD20 (rituximab), destruction of B cells could take place based on the induction of apoptosis, complement-mediated cytolysis, and antibody-dependent, cell-mediated cytoxicity [23].These agents have been introduced clinically and have been used frequently with other modalities systemically. One little series concerning rituximab use in OAL has been reported [24]; nevertheless, only one of eight patients had primary OAL, and just 2 of eight patients obtained rituximab alone. The patient with singular OAL additionally received radiation, cyclophosphamide, vincristine, and prednisone. Both patients getting antibody alone showed only partial responses or reoccurrence. The study did not divide the effects of the other therapies from the effect of the rituximab despite claiming" good effect of the rituximab." This writer has handled instances of primary OAL with systemic participation where rituximab in combined therapy led to partial regression, whereas in other patients no effect was seen.

Antimicrobial treatment

Maybe one of the most amazing development in the field of lymphoma management is the searching for that, in microbial-associated MALT lymphomas, antimicrobial treatment can bring about remission. This effect is best described for gastric lymphoma with antimicrobial therapy directed versus H pylori. The formerly talked about information associating OAL with C psittaci additionally described the first patients with OAL treated with antibiotic against the prompting agent [18].Seven patients with evidence of C psittaci in the tumor and peripheral blood mononuclear cells were treated with doxycycline, 100 mg three times daily, for 3 weeks. All the treated patients showed eradication of chlamydial DNA from peripheral blood mononuclear cells. Two of four patients with measurable OAL showed unbiased actions. The author and his colleagues have just recently dealt with a patient with RLH influencing the orbit and numerous lymph nodes

with doxycycline. A quick subjective and unbiased response was observed. Refresher courses are had to confirm this infectious association and those with various other possible prompting pathogens.

Conclusion:

The incidence of OAL, specifically ocular adnexal MALT lymphoma, has risen worldwide over the last couple of decades.Advances in our understanding of the immunophenotypic and genetic changes in lymphoma cell lines have caused a better understanding of the pathogenesis of the illness. The function of C. psittaci in the pathogenesis in the pathogenesis of ocular adnexal MALT lymphoma and the use of anti-biotics as a therapy alternative still need to be clarified by further collaborative international studies. Staging and histologic subtyping are essential in the design of optimum therapeutic program and determination of prognosis, as about 15% of situations of OAL existing with disseminated illness. A new TNM-based staging system has been created that will permit more accurate assessment of the risk of systemic disease and lymphoma-related death. New modalities of treatment including immunotherapy with anti-CD20 antibody and radioimmunotherapy offer distribution of improved cure rate and the delivery of curative treatment at much lower doses of radiation.

Reference:

1. Bairey O, Kremer I, Rakowsky E, et al. Orbital and adnexal involvement in systemic non-Hodgkin's lymphoma. Cancer. 1994;73:2395–2399.
2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphoma. Cancer. 1972;29:252–260.
3. Moslehi R, Devesa SS, Schairer C, et al. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. J Natl Cancer Inst. 2006;98:936–939.
4. Stefanovic A, Lossos IS. Extranodal marginal zone lymphoma of the ocular adnexa. Blood. 2009;114:501–510.
5. Knowles DM, Jakobiec FA, McNally L, et al. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol. 1990;21:959–973.

6. Johnson TE, Tse DT, Byrne GE Jr. Ocular adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg. 1999;15:171–179.
7. Cho EY, Han JJ, Ree HJ, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone B-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. Am J Hematol. 2003;73:87–96.
8. Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007; 31:170–184.
9. Demirci H, Shields CL, Karatza EC, et al. Orbital lymphproliferative tumors: analysis of clinical features and systemic involvement in 160 cases. Ophthalmology. 2008;115: 1626–1631.
10. Margo CE, Mulla ZD. Malignant tumors of the orbit. Analysis of the Florida cancer registry. Ophthalmology. 1998;105:185–190.
11. Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL, eds. WHO classification of Tumours of the Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:214–217.
12. Cox JD, Komaki R, Kun LE, et al. Stage III nodular lymphoreticular tumors (non-Hodgkin's lymphoma): results of central lymphatic irradiation. Cancer 1981; 47(9):2247 – 52.
13. Tsang RW, Gospodarowicz MK, O'Sullivan B. Staging and management of localized non-Hodgkins lymphomas: variations among experts in radiation oncology. Int J Radiat Oncol Biol Phys 2002;52(3): 643 – 51.
14. Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol 2001;59:139 – 44.
15. Coupland SE, Hellmich M, Auw-Haedrich C, et al. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol 2004;242:130 – 45.
16. Shields CL, Shields JA, Carvahlo C, et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. Ophthalmology 2001;108:979 – 84.
17. Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 2000;84:907 – 13.
18. Ferreri AJ, Guidoboni M, De Conciliis C, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586 – 94.
19. Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 2002;52(3):657 – 63.
20. Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multi-institutional, retrospective review of 50 patients. Cancer 2003;98(4):865 – 71.
21. Regueiro CA, Valcarcel FJ, Romero J, et al. Treatment of conjunctival lymphomas by beta ray brachytherapy using a strontium-90-yttrium-90 applicator. Clin Oncol 2002;14(6):459 – 63.

22. Blasi MA, Gherlinzoni F, Calvisi G, et al. Local chemotherapy interferon-a for conjunctival mucosaassociated lymphoid tissue lymphoma. Ophthalmology 2001;108(3):559 – 62.
23. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927.
24. Cartron G, Watier H, Golay J, et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635 – 42.
25. Sullivan TJ, Grimes D, Bunce I. Monoclonal antibody treatment of orbital lymphoma. Ophthal Plast Reconstr Surg 2004;20:103 – 6.